Evidence map›Paper›PMID 34578862›Full record

Trial reportNutrients2021

Supplementation of 1-Kestose Modulates the Gut Microbiota Composition to Ameliorate Glucose Metabolism in Obesity-Prone Hosts.

Ayako Watanabe, Takumi Tochio, Yoshihiro Kadota, Motoki Takahashi, Yasuyuki Kitaura, Hirohito Ishikawa, Takanori Yasutake, Masahiro Nakano, Hiroe Shinohara, Toru Kudo and 4 more

Open access · goldAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Nutrients, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 26 citations in OpenAlex.

  1. Trial
  2. Trial
  3. A Hot Water Extract ofNutrients · 2022
    Trial
  4. Review
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Gut microbiota and obesity: New insights.Frontiers in nutrition · 2022
    Review
  15. Gut Microbiota: An Important Player in Type 2 Diabetes Mellitus.Frontiers in cellular and infection microbiology · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

Ayako WatanabeLaboratory of Nutritional Biochemistry, Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Aichi, Japan.ORCID 0000-0001-7676-7476
Takumi TochioDepartment of Gastroenterology and Hepatology, Fujita Health University, Toyoake 470-1192, Aichi, Japan.
Yoshihiro KadotaB Food Science Co., Ltd., Chita 478-0046, Aichi, Japan.
Motoki TakahashiLaboratory of Nutritional Biochemistry, Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Aichi, Japan.
Yasuyuki KitauraLaboratory of Nutritional Biochemistry, Department of Applied Biosciences, Graduate School of Bioagricultural Sciences, Nagoya University, Nagoya 464-8601, Aichi, Japan.
Hirohito IshikawaHealthcare Systems Co., Ltd., Nagoya 466-0058, Aichi, Japan.ORCID 0000-0002-1988-0218
Takanori YasutakeHealthcare Systems Co., Ltd., Nagoya 466-0058, Aichi, Japan.
Masahiro NakanoPreventive Medical Center, Shin Oyama City Hospital, Oyama 323-0827, Tochigi, Japan.
Hiroe ShinoharaPreventive Medical Center, Shin Oyama City Hospital, Oyama 323-0827, Tochigi, Japan.
Toru KudoMetabologenomics, Inc., Tsuruoka 997-0052, Yamagata, Japan.
Yuichiro NishimotoMetabologenomics, Inc., Tsuruoka 997-0052, Yamagata, Japan.
Yoshinori MizuguchiMetabologenomics, Inc., Tsuruoka 997-0052, Yamagata, Japan.
Akihito EndoDepartment of Food, Aroma and Cosmetic Chemistry, Faculty of Bioindustry, Tokyo University of Agriculture, Abashiri 099-2493, Hokkaido, Japan.ORCID 0000-0002-7108-1202
Yoshiharu ShimomuraDepartment of Food and Nutritional Sciences, College of Bioscience and Biotechnology, Chubu University, Kasugai 487-8501, Aichi, Japan.ORCID 0000-0003-4345-0768
Nagoya University · JPChubu University · JPFujita Health University · JPTokyo University of Agriculture · JP

Funding

B Food Science Co., Ltd. B Food Science Co., Ltd.
6 · The paper itself

Abstract

Insulin resistance leads to the onset of medical conditions such as type 2 diabetes, and its development is associated with the alteration in the gut microbiota. Although it has been demonstrated that supplementation with prebiotics modulates the gut microbiota, limited evidence is available for effects of prebiotics on insulin resistance, especially for humans. We investigated the prebiotic effect of 1-kestose supplementation on fasting insulin concentration in obesity-prone humans and rats. In the preliminary study using rats, the hyperinsulinemia induced by high-fat diet was suppressed by intake of water with 2% (

Indexed as

Dietary SupplementsAdultAnimalsDisease Models, AnimalDouble-Blind MethodFemaleGastrointestinal MicrobiomeGlucoseHumansJapanMaleMiddle AgedObesityRatsRats, Sprague-DawleyTrisaccharides1-kestoseGlucoseTrisaccharidesBifidobacteriumgut microbiotainsulin resistanceobesityprebiotics

Identifiers

PMID34578862
PMCPMC8470827
OpenAlexW3196748347

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.